Benzimidazole derivatives : an important scaffold for the development of newer angiotensin receptor antagonists

Abstract EN

Hypertension is a major cause of death worldwide as well as one of the main causes of death in Saudi Arabia.

The prevalence of this disease is increasing in all age groups throughout the world which advocates that there is a need for more research in the field of hypertension.

The renin angiotensin system (RAS) is implicated in the pathogenesis of hypertension.

The renin inhibitors, angiotensin converting enzyme (ACE) inhibitors, and angiotensin II receptor (AT1) antagonists are the drugs that affect renin angiotensin system to control hypertension.

Recently, benzimidazole derivatives have emerged as an important scaffold for the development of angiotensin II, Type I (AT1) receptor antagonists for the treatment of hypert.

Three benzimidazole derivatives, namely, candesrtan, telmisartan, and azilsartan, have already been approved by the USFDA for the treatment of hypertension and related cardiac conditions.

Based on the reported structure activity relationship studies and literature, newer benzimidazole derivatives as AT1 receptor antagonists are being developed to tackle the issues related to hypertension and related cardiac conditions with emphasis to maintain their potency, duration of action, and bioavailability.

Many reviews have been published that provide the importance of benzimidazole derivatives in medicinal chemistry and in the development of medicinal compounds for clinical use.

However, this review highlights the development of newer benzimidazole derivatives as potential AT1 receptor antagonists that may be able to see the light of future as approved drugs for the treatment of hypertension.